MUC1 Inhibition Overcomes Chemotherapy Resistance in Acute Myeloid Leukemia
Myrna Nahas, Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Rebecca Karp(Beth Israel Deaconess Medical Center), Maxwell Coll, Hasan Rajabi(Harvard University), David Avigan(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Donald Küfe(Dana-Farber Cancer Institute), Malgorzata McMasters(Beth Israel Deaconess Medical Center), Salvia Jain(Broad Institute), Athalia R. Pyzer, Michal Bar‐Natan(NewYork–Presbyterian Hospital), Dina Stroopinsky(Beth Israel Deaconess Medical Center), James D. Levine(Beth Israel Deaconess Medical Center), Ashujit Tagde(Dana-Farber Cancer Institute), Kristen Palmer(Beth Israel Deaconess Medical Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center)
Cited by 2
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma
|Journal of Clinical Oncology|2002|1.2k
Interleukin-2 and Regulatory T Cells in Graft-versus-Host Disease
|New England Journal of Medicine|2011|1.1k